2024
Cystic Fibrosis Bacteriophage Study at Yale (CYPHY)
Stanley G, Cochrane C, Chan B, Kortright K, Rahman B, Lee A, Vill A, Sun Y, Stewart J, Britto-Leon C, Harris Z, Talwalker J, Shabanova V, Turner P, Koff J. Cystic Fibrosis Bacteriophage Study at Yale (CYPHY). 2024, a6808-a6808. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6808.Peer-Reviewed Original Research
2023
41 CYstic Fibrosis bacterioPHage study at Yale (CYPHY)
Chan B, Kortright K, Stanley G, Cochrane C, Lee A, Vill A, Sun Y, Stewart J, Britto-Leon C, Harris Z, Talkwalkar J, Shabanova V, Turner P, Koff J. 41 CYstic Fibrosis bacterioPHage study at Yale (CYPHY). Journal Of Cystic Fibrosis 2023, 22: s22. DOI: 10.1016/s1569-1993(23)00976-1.Peer-Reviewed Original Research
2017
Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis
Talwalkar JS, Koff JL, Lee HB, Britto CJ, Mulenos AM, Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. Journal Of The Academy Of Consultation-Liaison Psychiatry 2017, 58: 343-354. PMID: 28576305, DOI: 10.1016/j.psym.2017.04.001.Peer-Reviewed Original ResearchConceptsCFTR modulator therapyCystic fibrosisModulator therapyNovel therapiesCF transmembrane regulatorCFTR modulatorsCentral nervous system functionNovel CF therapiesManagement of depressionWorse medical outcomesMental health specialistsDrug-drug interactionsNervous system functionMental health variablesTreatment guidelinesClinical outcomesMedication interactionsCF centersComorbid depressionCF RegistryAnxiety screeningCF teamNovel agentsHigh riskMedical outcomes